EDAP Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of -36.13% compared to EDAP TMS SA's net margin of -13.56%. EDAP TMS SA's return on equity of -56.97% beat Ascendis Pharma A/S's return on equity of -880.05%.

EDAP TMS SA has a consensus price target of $6.83, signalling upside risk potential of 45.08%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $282.67 which suggests that it could grow by 25.48%. Given that EDAP TMS SA has higher upside potential than Ascendis Pharma A/S, analysts believe EDAP TMS SA is more attractive than Ascendis Pharma A/S.

EDAP TMS SA has a beta of -0.158, which suggesting that the stock is 115.787% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.436, suggesting its less volatile than the S&P 500 by 56.356%.

EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Ascendis Pharma A/S quarterly revenues of $288.1M. EDAP TMS SA's net income of -$5.9M is higher than Ascendis Pharma A/S's net income of -$39.1M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 2.50x versus 16.58x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

EDAP TMS SA has a consensus price target of $6.83, signalling upside risk potential of 45.08%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 15232.01%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than EDAP TMS SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than EDAP TMS SA.

EDAP TMS SA has a beta of -0.158, which suggesting that the stock is 115.787% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.

EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

EDAP TMS SA quarterly revenues are $16.2M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 2.50x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of 1.68%. EDAP TMS SA's return on equity of -56.97% beat Cellectis SA's return on equity of -31.08%.

EDAP TMS SA has a consensus price target of $6.83, signalling upside risk potential of 45.08%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 85.9%. Given that Cellectis SA has higher upside potential than EDAP TMS SA, analysts believe Cellectis SA is more attractive than EDAP TMS SA.

EDAP TMS SA has a beta of -0.158, which suggesting that the stock is 115.787% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.833, suggesting its more volatile than the S&P 500 by 183.275%.

EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Cellectis SA quarterly revenues of $35M. EDAP TMS SA's net income of -$5.9M is lower than Cellectis SA's net income of $586.4K. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 2.50x versus 4.85x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat DBV Technologies SA's return on equity of -280.59%.

EDAP TMS SA has a consensus price target of $6.83, signalling upside risk potential of 45.08%. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 87.14%. Given that DBV Technologies SA has higher upside potential than EDAP TMS SA, analysts believe DBV Technologies SA is more attractive than EDAP TMS SA.

EDAP TMS SA has a beta of -0.158, which suggesting that the stock is 115.787% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

EDAP TMS SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than DBV Technologies SA's net income of -$33M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 2.50x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.